This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Varga, J. Articles by Dickman, A. Search for Related Content PubMed PubMed Citation Articles by Varga, J. Articles by Dickman, A. Social Bookmarking                         What's this?

Ibuprofen to rofecoxib: What does it all mean and what do I do now?

Pain and Palliative Care Association, Orlando, Florida

Andrew Dickman, MSc, MRPharmS

Palliative Care, Whiston Hospital, Merseyside, United Kingdom

NSAIDs are used throughout the World Health Organization three-step analgesic ladder, and are indicated for pain in all stages of malignancy. Side-effects are common with NSAIDs. Much has been written about NSAIDs and COX, since the discovery of COX-1 and COX-2 isoforms. How do you choose the appropriate NSAID? The choice of NSAID continues to be dependent upon associated gastroduodenal toxicity and the related risk factors of individual patients. Choosing the appropriate NSAID should minimize the likelihood of needing additional medications to manage adverse effects and symptoms caused by the NSAID therapy itself.

Key Words: celecoxib • COX inhibitors • COX-1 • COX-2 • diclofenac • etodolac • ibuprofen • meloxicam • naproxen • NSAIDs • piroxicam • rofecoxib • salicylates • sulindac

American Journal of Hospice and Palliative Medicine®, Vol. 18, No. 4, 271-274 (2001)
DOI: 10.1177/104990910101800412


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?